About UCSF Search UCSF UCSF Medical Center

Jennifer L. Clarke, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
clarke_jennifer

Assistant Professor of Clinical Neurology and Neurological Surgery, UCSF

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles


Additional Websites


Education

California Institute of Technology (Caltech), Pasadena, CA, B.S., 1995, Chemistry, With Honor
University of California, San Francisco, M.D., 2002, Medicine
University of California, Berkeley, M.P.H., 2001, Health Policy and Mgmt
St. Mary’s Medical Center, San Francisco, 06/03, Intern, Internal Medicine
University of California, San Francisco, 06/06, Resident, Neurology
Memorial Sloan-Kettering Cancer Center, 06/08, Fellow, Neuro-oncology


Professional Experience

  • 6/95-8/97
    Combion, Inc.
  • 7/02-6/03
    St. Mary’s Medical Center, San Francisco Intern Medicine
  • 7/03-6/06
    University of California, San Francisco Resident Neurology
  • 7/05-6/06
    University of California, San Francisco Chief Resident Neurology
  • 7/06-6/08
    Memorial Sloan-Kettering Cancer Center Fellow Neuro-Oncology
  • 7/07-6/08
    Memorial Sloan-Kettering Cancer Center Chief Fellow Neuro-Oncology
  • 8/08-6/10
    University of California, San Francisco Assistant Clinical Professor of Neurology and Neurological Surgery (Division of Neuro-Oncology)
  • 8/10 – present
    University of California, San Francisco Assistant Professor of Clinical Neurology and Neurological Surgery (Division of Neuro-Oncology)

Honors & Awards

  • 1999
    Nomination for “An Outstanding Lecture” UCSF Class of 2001
  • 2000
    University Fellowship, UC-Berkeley
  • 2000
    Award for “An Outstanding Lecture” UCSF Class of 2002
  • 2001
    UCSF Class of 1966 Scholarship
  • 2003
    Intern of the Year, St. Mary’s Medical Center
  • 2008
    ASCO Foundation Merit Award
  • 2009
    Awarded a fellowship to the 2nd Annual Clinical Trials Methods Course in Neurology, in Vail, Colorado, August 17-23, 2009; the course is sponsored by NINDS

Selected Publications

  1. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6.
    View on PubMed
  2. Nagpal S, Clarke JL. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45.
    View on PubMed
  3. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42.
    View on PubMed
  4. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
    View on PubMed
  5. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5.
    View on PubMed
  6. Clarke JL, Deangelis LM. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27.
    View on PubMed
  7. Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31.
    View on PubMed
  8. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
    View on PubMed
  9. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9.
    View on PubMed
  10. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
    View on PubMed
  11. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar; 67(3):279-83.
    View on PubMed
  12. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6.
    View on PubMed
  13. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.
    View on PubMed
  14. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 Aug 10; 27(23):3861-7.
    View on PubMed
  15. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009 May; 9(3):241-6.
    View on PubMed
  16. Cheng SH, Horng CF, Clarke JL, Tsou MH, Tsai SY, Chen CM, Jian JJ, Liu MC, West M, Huang AT, Prosnitz LR. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006 Apr 1; 64(5):1401-9.
    View on PubMed
  17. Clarke JL, Johnston SC, Farrant M, Bernstein R, Tong D, Hemphill JC. External validation of the ICH score. Neurocrit Care. 2004; 1(1):53-60.
    View on PubMed

Go to UCSF Profiles, powered by CTSI